Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Dual orexin receptor antagonist (DORA) (1) ·
[[:Category:Antigout_agents|Antigout agent]] (1) ·
[[:Category:Antihyperuricemic_agents|Antihyperuricemic agent]] (1) ·
[[:Category:Beta-3_agonists|β3 adrenergic agonist]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (first-generation)]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (2) ·
[[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]] (2) ·
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1) ·
[[:Category:Xanthine_oxidase_inhibitors|Xanthine oxidase inhibitor]] (1)
mechanism:
uses:
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
'"`UNIQ--vote-00000050-QINU`"' (1) ·
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1) ·
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"' (1)
starting dose:
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) ·
2 g PO BID with meals (4 g/d total) (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) ·
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) ·
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections (1)
preparations:
0.5 g, 1 g capsules (1) ·
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) ·
100 mg, 300 mg tablets; IV 500 mg vial (1) ·
25 mg, 50 mg tablets (1) ·
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) ·
250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets (1)
fda max: (Click arrow to add another value)
onset:
Hours (1) ·
Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation (1) ·
Symptom improvement within weeks (1) ·
Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) ·
Triglyceride lowering at 4-8 weeks; CV benefit emerges over months (1) ·
~30 min (1)
duration:
halflife:
1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' (1) ·
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-000004F2-QINU`"' (1) ·
~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1) ·
~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"' (1)
bioavailability:
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' (1) ·
Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) ·
Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' (1) ·
~62% (1) ·
~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1)
pregnancy:
Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; avoid (1) ·
Limited human data<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 6 results in range #1 to #6.